Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Genocea...
-
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced two...
-
CAMBRIDGE, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...
-
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...
-
Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand apart from in silico methods of neoantigen identificationConference call today at 9:00 am ET ...
-
CAMBRIDGE, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a...
-
CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark,...
-
- Company files IND for lead neoantigen vaccine program, GEN-009 - - ATLAS™ platform continues to stand apart from in silico methods of neoantigen identification - - Conference call today at 9 am ET -...
-
CAMBRIDGE, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a...
-
- Company plans to initiate Phase 1/2a clinical program later this year - - Top-line immune response data expected in the first half of 2019 - CAMBRIDGE, Mass., April 30, 2018 (GLOBE NEWSWIRE) --...